Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
    • Media
  1. Home
  2. Investors

Press releases

19.05.2022

DEINOVE- Second convening to a Combined General Meeting on May 30, 2022

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...
16.05.2022

DEINOVE reaches the first milestones of the Boost-ID project, selected as part of the France Relance plan, with the operational installation of its microfluidic screening platform

The Boost-ID project was selected and financed under the France Relance plan The installation and qualification, in DEINOVE's premises in...
08.04.2022

DEINOVE presents its financial results and the advancement of its programs for 2021

Favorable opinion of the DSMB and continuation of the Phase II of of DNV3837 in the treatment of Clostridioides difficile infection ◦...
07.04.2022

The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada

The extension of the clinical trial in Canada will add 5 new sites to those already active in the United States and accelerate patient...
23.03.2022

Issuance of a 4th tranche of €500,000 of notes convertibles into new shares

DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating...
17.03.2022

Michael MOUREZ joins the DEINOVE team as Chief Innovation Officer

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...
02.03.2022

Thanks to the AGIR program, DEINOVE has become a unique French industrial biotech in the fight against antibiotic resistance

The AGIR program, supported by the Investments for the Future Program, has allowed DEINOVE and the Charles Viollette Institute to develop...
26.01.2022

Issuance of 3rd tranche of €500,000 of notes convertibles into new shares

DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating...
06.01.2022

DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections

The DSMB* considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the clinical trial The...
15.12.2021

Issuance of 2nd tranche of €500,000 of notes convertibles into new shares

DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating...
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »

Investors

  • Corporate governance
    • Board of Directors
    • Executive Committee
  • DEINOVE Shares
  • Financial Calendar
  • Documentation Center
    • Financial Reports
    • Investors slide deck
    • Analyst Coverage
    • Number of Shares and Voting Rights
    • Newsletter to Shareholders
    • Shareholders' Meetings
    • Declaration of transactions performed on company securities
    • Liquidity Agreement
    • Public offerings - Documentation
    • Bonds Convertible into Shares (OCA)
  • Press releases
  • Investor relations
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

    

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home